secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001802768-23-000027
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q3 2023: $637M Adj Cash Receipts (+7% YoY); raises FY23 guidance
-------------------------------------------------------------------------------

- Adjusted Cash Receipts of $637M (+7% YoY); operating cash flow $574M (+6%).
- Raised FY 2023 guidance for Adjusted Cash Receipts to $2,950M-$3,000M (prev. $2,900M-$2,975M).
- Year-to-date announced transactions of up to $3.8B, including $2.1B in upfront payments.
- CF franchise royalties $238M (+14%); Trelegy $58M (+36%); Evrysdi $16M (+64%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000180276823000027/0001802768-23-000027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000180276823000027/rprx-20231108.htm
  HTML page:      https://secwatch.observer/filing/0001802768-23-000027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer